Regarding etanercept treatment, Liu et al. showed that certain polymorphisms in the TNFα gene promoter could predict a good response to TNFα-blocking therapies, especially for etanercept treatment in patients with spondyloarthritis (276). This evidence concerns the gene TNF and spondyloarthropathy.